- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00086502
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patient has type 2 diabetes mellitus (T2DM)
- Patient is 18 years of age (or older)
- Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period
Exclusion Criteria:
- Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis
- Patient required insulin within the prior 8 weeks
- Patient is on a weight loss program and is not in the maintenance phase
- Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks
- Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate)
- Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease
- Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis)
- Patient has any of the following disorders within the past 6 months:
Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder.
- Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months
- Patient has severe peripheral vascular disease
- Patient has congestive heart failure
- Patient is HIV positive
- Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
- Patient has a history of neoplastic disease
- Patient has a history of alcohol or drug abuse within the past 3 years
- Patient has viral hepatitis (hepatitis B or C)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
Andre navn:
Metformin rescue for patients meeting pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8
Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
|
|
Aktiv komparator: Sitagliptin 100 mg
|
Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
Andre navn:
Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
Andre navn:
Metformin rescue for patients meeting pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8 |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24
Tidsramme: Baseline and week 24
|
HbA1c is measured as a percent.
Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.
|
Baseline and week 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24
Tidsramme: Baseline and week 24
|
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
|
Baseline and week 24
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Glukosemetabolismeforstyrrelser
- Metabolske sykdommer
- Sykdommer i det endokrine systemet
- Sukkersyke
- Diabetes mellitus, type 2
- Hypoglykemiske midler
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Proteasehemmere
- Inkretiner
- Dipeptidyl-Peptidase IV-hemmere
- Metformin
- Pioglitazon
- Sitagliptinfosfat
Andre studie-ID-numre
- 0431-019
- Formally-A0604T2DPT
- 2006_410
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .